Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company’s therapeutics products focuses on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead product candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. It also develops STP355 for the treatment of multiple solid tumors, including breast cancer, melanoma and colorectal cancer; STP369 to treat head and neck and bladder cancer; STP122G to treat coagulation disorders; STP125G to treat hypertriglyceridemia and a potential anticoagulant therapy; and STP144G for the treatment of complement diseases. The company is also developing RV-1730, a vaccine for Covid-19 and respiratory syncytial virus; STP152G for ATTR amyloidosis indication; STP136G to treat hypertension; STP247G for the treatment of complement diseases; and STP237G to treat hypertension and hypertriglyceridemia diseases. Sirnaomics Ltd. was founded in 2007 and is headquartered in Germantown, Maryland.